More than half of US adults could benefit from GLP-1 medications, researchers find

In a new analysis of national data, researchers at the Richard A. and Susan F. Smith Center for Outcomes Research at Beth Israel Deaconess Medical Center (BIDMC) estimated that 137 million U.S. adults, more than half of all adults, are eligible for semagludtide for weight loss, diabetes management, or prevention of recurrent cardiovascular events.

Facebook Comments